Rosacea Clinical Trials
Here are the 5 most popular medical studies for rosacea
Tetracycline Antibiotic
Minocycline Gel for Papulopustular Rosacea
This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.
Popular filter options for rosacea trials
Rosacea Clinical Trials With No Placebo
View 12 rosacea medical studies that do not have a placebo group.
Anti-parasitic
Ivermectin + Digital Interaction for Rosacea
This trial will test whether or not weekly digital interactions and routine measurement of TEWL rates and SC hydration levels will help patients stick to their ivermectin therapy and prevent disease relapse.
Antibiotic
Microbiome Analysis for Rosacea
This trial found that the skin and gut microbiome of rosacea patients differs from individuals without rosacea. They also found that the microbiome suffers from unique derangements in rosacea patients following antibiotic therapy.
Frequently Asked Questions
Introduction to rosacea
What are the top hospitals conducting rosacea research?
Exciting developments are taking place in the realm of clinical trials for treating rosacea, a common and often frustrating skin condition. In New york City, the Icahn School of Medicine at Mount Sinai is leading the way with its active trial focused on combating this condition. This groundbreaking research represents their first recorded rosacea trial, initiated in 2023. Similarly, Integrative Skin and Research in Sacramento is making significant strides with their own active rosacea trial that began in 2023 as well.
Meanwhile, The Centre for Clinical Trials located in Oakville is also dedicated to advancing our understanding of rosacea through an ongoing clinical study launched just recently in 2023. Additionally, SKiN Centre for Dermatology based out of Peterborough is actively engaged in a similar endeavor—a current trial seeking innovative solutions for those affected by this skin disorder.
Last but not least, K. Papp Clinical Research situated in Waterloo has made notable contributions to the field as well with their own active rosacea trial underway since 2023.
While each hospital's involvement may seem limited at present with only one active and all-time recorded trials under their belts thus far; it's important to recognize that these endeavors mark crucial steps towards finding effective treatments and improving quality of life for individuals living with rosacea.
As researchers continue to explore new avenues and uncover novel approaches to tackling this complex condition collectively across various locations; there remains hope that these efforts will lead us closer than ever before to unlocking breakthroughs which could transform how we approach managing and ultimately curing rosacea—an accomplishment that would bring relief not only locally but globally as well
Which are the best cities for rosacea clinical trials?
When it comes to rosacea clinical trials, several cities are at the forefront of research. Austin, Texas has 2 active trials investigating treatments such as Topical Powder and BPX-04 Active. New york, New York is also conducting 1 trial focused on PF-07038124 and other potential therapies. Additionally, Sacramento in California, Oakville in Ontario, and Peterborough in Ontario each have 1 ongoing trial exploring various treatment options for rosacea. These cities offer individuals with rosacea opportunities to participate in cutting-edge clinical trials that may lead to improved management of this skin condition.
Which are the top treatments for rosacea being explored in clinical trials?
Exciting developments are emerging in the field of rosacea treatment, with several promising options being explored in ongoing clinical trials. One such contender is PF-07038124, currently undergoing one active trial dedicated to rosacea. Another potential breakthrough lies in Doxycycline 40 MG (20mg twice daily), also involved in one active trial for this skin condition. Additionally, a topical powder has shown promise and is under investigation through its participation in another ongoing rosacea trial. These innovative treatments offer hope for individuals seeking relief from the symptoms of rosacea and may soon provide effective solutions to manage this chronic skin disorder.
What are the most recent clinical trials for rosacea?
Exciting advancements in rosacea treatment have emerged from recent clinical trials. One promising study introduced PF-07038124, a potential game-changer for those with this skin condition. This Phase 2 trial demonstrated its efficacy and safety and offers hope for improved management of rosacea symptoms. Another notable trial explored the use of Doxycycline 40 MG in patients with rosacea, aiming to further enhance existing treatment options. Lotilaner Gel (TP-04) has also shown promise as a potential therapeutic option through its Phase 2 trial. While these developments represent significant progress, it's worth mentioning that earlier studies on topical powder and ivermectin have paved the way by providing valuable insights into treating rosacea effectively.
What rosacea clinical trials were recently completed?
Recently completed clinical trials for rosacea have shown promising results in advancing treatment options for this common skin condition. In March 2022, Journey Medical Corporation successfully concluded a trial examining the efficacy of DFD-29, and Candela Corporation also wrapped up their study on Oxymetazoline HCL 1% Cream in January 2019. These investigations contribute valuable insights into potential therapeutic approaches to address the symptoms of rosacea and offer hope for patients seeking effective relief.